AMRI announces final results from ALB-127158 Phase I clinical research on obesity AMRI announced today the final results from its Phase I clinical studies on its novel MCH1 receptor antagonist, ALB-127158 through the 29th Annual Scientific Meeting of the Obesity Culture in Orlando, Fla. Nicholas Moore, Ph impotance .D., director of development and pharmacology at AMRI, reported results from a second Phase I study showing cerebrospinal liquid drug levels were achieved with a single 400 mg oral dosage of ALB-127158. The finding is normally significant in that this implies human brain/CNS penetration and suggests the compound will reach the drug target receptor in the brain.
AMGA announces participation of 19 health systems in ACO Development Collaborative The American Medical Group Association today announced 19 leading medical groups and organized systems of care which will be taking part in its ACO Advancement Collaborative, scheduled to have its first meeting with the AMGA National Summit on Accountable Treatment Organizations . These organizations represent more than 10,500 providers serving around 5 million patients in the United States. AMGA and its member medical groups are the vanguard of healthcare in America, delivering and developing effective, efficient healthcare to the patients they serve, said Donald W. Fisher, Ph.D., CAE, president and ceo at AMGA. For over a decade, AMGA has used learning collaboratives to improve organizational functionality through systematic change, and latest reform legislation has inspired members to utilize the ACO model as an impetus to transform the delivery and financing of treatment.